The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
Tirzepatide, the main ingredient in Mounjaro and Zepbound, is no longer in shortage, according to the U.S. Food and Drug ...
The fight against obstructive sleep apnea (OSA) has taken a monumental leap forward. For the first time, the U.S. Food and ...
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...
The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.